In Vitro Wound Healing of Tumor Cells: Inhibition of Cell Migration by Selected Cytotoxic Alkaloids

Overview

Journal BMC Pharmacol Toxicol

Publisher Biomed Central

Specialty Pharmacology

Date 2019 Jan 11

PMID 30626448

Citations 42

Authors

Xiaojuan Wang

Charlotte Caroline Decker

Laura Zechner

Sonja Krstin

Michael Wink

Affiliations

Soon will be listed here.

Abstract

Background: Cell migration is involved in several pathological processes such as tumor invasion, neoangiogenesis and metastasis. Microtubules are needed in directional migration.

Methods: To investigate the effects of microtubule-binding agents (paclitaxel, vinblastine, colchicine, podophyllotoxin), benzophenanthridine alkaloids (sanguinarine, chelerythrine, chelidonine) and other anti-tumor drugs (homoharringtonine, doxorubicin) on cell migration, we performed the in vitro wound healing assay. The interactions between selected alkaloids and microtubules were studied via U2OS cells expressing microtubule-GFP markers.

Results: The microtubule-binding natural products paclitaxel, vinblastine, colchicine and podophyllotoxin significantly altered microtubule dynamics in living cells and inhibited cell migration at concentrations below apparent cytotoxicity. The benzophenanthridine alkaloid sanguinarine, chelerythrine and chelidonine which affected microtubules in living cells, did not inhibit cell migration. Homoharringtonine (protein biosynthesis inhibitor) and doxorubicin significantly inhibited cell migration, however, they did not exert obvious effects on microtubules.

Conclusion: In this study, we demonstrated that microtubule-binding agents are effective anti-migrating agents; moreover, homoharringtonine and doxorubicin can be referred as anti-migrating agents, but direct microtubule dynamics are not involved in their mode of action. Our study provides evidence that some alkaloids and other microtubule-binding natural products may be interesting candidates for the development of novel agents against metastasis.

Citing Articles

Cytotoxic and immunomodulatory properties of Tinospora cordifolia, Boerhaavia diffusa, Berberis aristata, and Ocimum basilicum extracts against HPV-positive cervical cancer cell line.

Vaghasia H, Patel R, Prajapati J, Shah K, Saraf M, Rawal R BMC Complement Med Ther. 2025; 25(1):59.

PMID: 39962423 PMC: 11834557. DOI: 10.1186/s12906-025-04817-x.

Tumor Suppressor miR-27a-5p and Its Significance for Breast Cancer.

Parrella P, Barbano R, Jonas K, Fontana A, Barile S, Rendina M Biomedicines. 2024; 12(11).

PMID: 39595190 PMC: 11592003. DOI: 10.3390/biomedicines12112625.

Direct visualization of emergent metastatic features within an ex vivo model of the tumor microenvironment.

Anandi L, Garcia J, Ros M, Janska L, Liu J, Carmona-Fontaine C Life Sci Alliance. 2024; 8(1).

PMID: 39419548 PMC: 11487089. DOI: 10.26508/lsa.202403053.

Copper selective 8-aminoquinoline based tetradentate chelators as anticancer agents.

Guan Y, Nguyen M, Robert A, Liu Y, Meunier B RSC Med Chem. 2024; 15(9):3048-3056.

PMID: 39309357 PMC: 11411617. DOI: 10.1039/d4md00171k.

Betanin-encapsulated starch nanoparticles: synthesis and cytotoxic effect on colon cancer.

Bhat S, Chandramohan S, Krishna G, Hiranmaya C, Pajaniradje S, Nair A 3 Biotech. 2024; 14(10):233.

PMID: 39297057 PMC: 11405737. DOI: 10.1007/s13205-024-04078-4.

References

Eun J, Koh G . Suppression of angiogenesis by the plant alkaloid, sanguinarine. Biochem Biophys Res Commun. 2004; 317(2):618-24. DOI: 10.1016/j.bbrc.2004.03.077. View

Quintas-Cardama A, Kantarjian H, Cortes J . Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. Cancer. 2009; 115(23):5382-93. DOI: 10.1002/cncr.24601. View

Lu J, Bao J, Chen X, Huang M, Wang Y . Alkaloids isolated from natural herbs as the anticancer agents. Evid Based Complement Alternat Med. 2012; 2012:485042. PMC: 3440018. DOI: 10.1155/2012/485042. View

Bijman M, van Nieuw Amerongen G, Laurens N, van Hinsbergh V, Boven E . Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther. 2006; 5(9):2348-57. DOI: 10.1158/1535-7163.MCT-06-0242. View

Yan J, Pang Y, Sheng J, Wang Y, Chen J, Hu J . A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells. Biochem Pharmacol. 2015; 97(1):51-61. DOI: 10.1016/j.bcp.2015.07.008. View

Wang X, Tanaka M, Krstin S, Peixoto H, Wink M . The Interference of Selected Cytotoxic Alkaloids with the Cytoskeleton: An Insight into Their Modes of Action. Molecules. 2016; 21(7). PMC: 6273799. DOI: 10.3390/molecules21070906. View

Kaur R, Kaur G, Gill R, Soni R, Bariwal J . Recent developments in tubulin polymerization inhibitors: An overview. Eur J Med Chem. 2014; 87:89-124. DOI: 10.1016/j.ejmech.2014.09.051. View

Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli M, Viale G . The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996; 2(11):1843-9. View

Field J, Kanakkanthara A, Miller J . Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function. Bioorg Med Chem. 2014; 22(18):5050-9. DOI: 10.1016/j.bmc.2014.02.035. View

10.

Kazemi Noureini S, Esmaili H . Multiple mechanisms of cell death induced by chelidonine in MCF-7 breast cancer cell line. Chem Biol Interact. 2014; 223:141-9. DOI: 10.1016/j.cbi.2014.09.013. View

11.

Narayanan V, Gutman J, Pollyea D, Jimeno A . Omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia. Drugs Today (Barc). 2013; 49(7):447-56. DOI: 10.1358/dot.2013.49.6.1980495. View

12.

Zhang Z, Mi C, Wang K, Wang Z, Li M, Zuo H . Chelidonine inhibits TNF-α-induced inflammation by suppressing the NF-κB pathways in HCT116 cells. Phytother Res. 2017; 32(1):65-75. DOI: 10.1002/ptr.5948. View

13.

Achkar I, Mraiche F, Mohammad R, Uddin S . Anticancer potential of sanguinarine for various human malignancies. Future Med Chem. 2017; 9(9):933-950. DOI: 10.4155/fmc-2017-0041. View

14.

Ganguly A, Yang H, Sharma R, Patel K, Cabral F . The role of microtubules and their dynamics in cell migration. J Biol Chem. 2012; 287(52):43359-69. PMC: 3527923. DOI: 10.1074/jbc.M112.423905. View

15.

Gewirtz D . A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol. 1999; 57(7):727-41. DOI: 10.1016/s0006-2952(98)00307-4. View

16.

Zhu Q, Jiang M, Liu Q, Yan S, Feng L, Lan Y . Enhanced healing activity of burn wound infection by a dextran-HA hydrogel enriched with sanguinarine. Biomater Sci. 2018; 6(9):2472-2486. DOI: 10.1039/c8bm00478a. View

17.

Ballestrem C, Wehrle-Haller B, Hinz B, Imhof B . Actin-dependent lamellipodia formation and microtubule-dependent tail retraction control-directed cell migration. Mol Biol Cell. 2000; 11(9):2999-3012. PMC: 14971. DOI: 10.1091/mbc.11.9.2999. View

18.

Vicente-Manzanares M, Choi C, Horwitz A . Integrins in cell migration--the actin connection. J Cell Sci. 2009; 122(Pt 2):199-206. PMC: 2714416. DOI: 10.1242/jcs.018564. View

19.

Tan I, Lai J, Yong J, Li S, Leung T . Chelerythrine perturbs lamellar actomyosin filaments by selective inhibition of myotonic dystrophy kinase-related Cdc42-binding kinase. FEBS Lett. 2011; 585(9):1260-8. DOI: 10.1016/j.febslet.2011.03.054. View

20.

Stanton R, Gernert K, Nettles J, Aneja R . Drugs that target dynamic microtubules: a new molecular perspective. Med Res Rev. 2011; 31(3):443-81. PMC: 3155728. DOI: 10.1002/med.20242. View